AGE MALES/FEMALES 0 - 3 days 8.0-20.0 mcg/dL 3 - 30 days 5.0-15.0 mcg/dL 31 days - 1 years 6.0-14.0 mcg/dL 1 - 5 years 4.5-11.0 mcg/dL 6 - 18 years 4.5-10.0 mcg/dL Normal adults 4.6 12.0 mcg/dL

The assay is unaffected by icterus (bilirubin is less than 37 mg/dL), hemolysis (Hb is less than 2300 mg/dL), lipemia (triglycerides is less than 2500 mg/dL) and biotin is less than 100 ng/mL (criterion: recovery within plus or minus 10% of initial value). In patients receiving therapy with high biotin doses (i.e. is greater than 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No interference was observed from rheumatoid factor (up to 2400 U/mL) and samples from dialysis patients. In vitro tests were performed on 15 commonly used pharmaceuticals. No interference with the assay was found. Autoantibodies to thyroid hormones can interfere with the assay. The risk of interference from potential immunological interactions between test components and rare plasma has been minimized by the inclusion of additives. In rare cases, interference due to extremely high titers of antibodies to ruthenium can occur. T4 reagent contains additives which minimize these effects. Extremely high titers of antibodies to streptavidin can occur in isolated cases and cause interference. For diagnostic purposes, the T4 findings should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.